ENGINEERING

SAN DIEGO, CA -- Accelrys Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP), today announced the availability of five top Accelrys software products on IBM eServer(R) pSeries(R) systems running AIX(R). These are the first product releases stemming from the recently announced global strategic alliance between IBM and Accelrys. The main goal of the alliance is to enhance drug research and development (R&D) operations by creating a collaborative information technology environment to help chemists and biologists develop new drugs faster, more efficiently, and at lower costs. The first commercially available Accelrys life sciences applications optimized to run on IBM eServer pSeries systems, including the new p690(R) server code named "Regatta," are: Wisconsin Package(R), CHARMm(R), Modeler(R), Delphi(R), and SeqFold(R). These five applications span rapidly developing aspects of drug discovery and bioinformatics in which genomic and proteomic analyses will become integrated to extend information that can be gleaned from existing research data. In addition, Accelrys will collaborate with IBM to port the majority of its top life sciences applications to IBM systems over the next three quarters of 2002. This aggressive product migration strategy is a key component of the collaboration between Accelrys and IBM. "We are very excited to offer these products on the IBM eServer pSeries so soon after our strategic alliance announcement," said Dr. Michael Stapleton, chief operating officer and executive vice president of Accelrys. "The IBM team has shown the skill and commitment necessary to facilitate the hardware transition happening in pharmaceutical research today. We're looking forward to delivering significant performance gains to our customers with the adoption of these products running on IBM servers." The porting of these products will also speed up the delivery of the Accelrys Discovery Studio(R) platform. Discovery Studio is an integrated set of Accelrys technologies that will offer broad access to key life sciences applications, while enabling effective capture and reuse of critical scientific information and knowledge, whether generated by Accelrys' portfolio of software products, in-house, or by third parties. Ultimately, Discovery Studio will provide an integrated information management infrastructure that will enable researchers from different scientific disciplines to collaborate to solve critical problems across genomics, chemistry and biology. "This announcement speaks volumes about the synergies between the two companies and about our mutual commitment to customers," said Dr. Caroline Kovac, general manager, IBM Life Sciences. "Accelrys is delivering five leading applications on IBM's server platform a month after the formation of our alliance. This milestone is a strong testament to our common goal of using innovative information technologies to bring new levels of efficiency to pharmaceutical R&D." Products ported to the IBM platform will initially operate on AIX servers, and will be designed to seamlessly integrate into the upcoming Discovery Studio enterprise client-server environment. In addition, Accelrys products that are Discovery Studio enabled will be available on a range of server environments, including AIX and other proprietary versions of UNIX as well as Windows NT(R) and Linux(R). The product roadmaps have been specifically designed and licensed to facilitate the transition from an isolated workstation environment to a collaborative enterprise computing model, recognizing the need to maintain data integrity, full application access and the ability to scale and deploy high performance compute resources dynamically. For more information visit www.ibm.com or www.accelrys.com .